The FDA's Assessment of Two Drugs for Chronic Weight Management

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · see citing works

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · see citing works

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study

Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716 · see citing works

Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP)

Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711 · see citing works

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561 · see citing works

Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study

O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 528 · see citing works

The Obesity Epidemic and Its Impact on Hypertension

Nguyen, T., & Lau, D. C. W. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.01.001 · Cited by 215 · see citing works

Use of topiramate in pregnancy and risk of oral clefts

Margulis, A. V., Mitchell, A. A., Gilboa, S. M., Werler, M. M., Mittleman, M. A., Glynn, R. J., & Hernández–Dı́az, S. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.07.008 · Cited by 178 · see citing works

Serotonergic Drugs and Valvular Heart Disease

Rothman, R., & Baumann, M. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902931524 · Cited by 134 · see citing works

Obesity and type 2 diabetes: which patients are at risk?

Garber, A. J. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2011.01536.x · Cited by 108 · see citing works

Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity

Hendricks, E. J., Greenway, F. L., Westman, E. C., & Gupta, A. K. (2011) · Obesity · doi:10.1038/oby.2011.94 · Cited by 97 · see citing works

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

Díaz, E. G., & Folgueras, T. M. (2011) · PubMed · doi:10.1590/s0212-16112011000300004 · Cited by 23 · see citing works

Withdrawal of Sibutramine for Weight Loss: Where Does This Leave Clinicians?

Czernichow, S., & Batty, G. D. (2010) · Obesity Facts · doi:10.1159/000316508 · Cited by 20 · see citing works

Long-term Drug Treatment for Obesity: A Systematic and Clinical Review

Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876 · see citing works

Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?

Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343 · see citing works

Phentermine and topiramate for the management of obesity: a review

Uwaifo, G. I., Cosentino, & Conrad, A. O. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s31443 · Cited by 242 · see citing works

Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis

Berglund, E. D., Liu, C., Sohn, J., Liu, T., Kim, M. H., Lee, C. E., Vianna, C. R., Williams, K. W., Xu, Y., & Elmquist, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70338 · Cited by 230 · see citing works

Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment

Zhang, Y., Liu, Q., Yu, J., Yu, S., Wang, J., Qiang, L., & Gu, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b04348 · Cited by 226 · see citing works

Obesity and reproduction: a committee opinion

Penzias, A. S., Azziz, R., Bendikson, K. A., Falcone, T., Hansen, K. R., Hill, M. J., Jindal, S., Kalra, S. K., Mersereau, J. E., Reindollar, R. H., et al. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.08.018 · Cited by 239 · see citing works

Obesity and reproduction: a committee opinion

(2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.08.018 · Cited by 216 · see citing works

The anti-obesity effect of green tea polysaccharides, polyphenols and caffeine in rats fed with a high-fat diet

Xü, Y., Zhang, M., Wu, T., Dai, S., Xu, J., & Zhou, Z. (2014) · Food & Function · doi:10.1039/c4fo00970c · Cited by 213 · see citing works

Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy

Veiby, G., Daltveit, A. K., Engelsen, B. A., & Gilhus, N. E. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7239-x · Cited by 196 · see citing works

Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles

Xue, Y., Xu, X., Zhang, X., Farokhzad, O. C., & Langer, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603840113 · Cited by 186 · see citing works

Pharmacotherapy of Obesity: Clinical Treatments and Considerations

Holes-Lewis, K., Malcolm, R. J., O'Neil, P. M., & Hermayer, K. L. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828abcfd · Cited by 188 · see citing works

Obesity: Current and potential pharmacotherapeutics and targets

Narayanaswami, V., & Dwoskin, L. P. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 184 · see citing works

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174 · see citing works

Evolution of pharmacological obesity treatments: focus on adverse side‐effect profiles

Krentz, A. J., Fujioka, K., & Hompesch, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12657 · Cited by 168 · see citing works

Lifestyle intervention in childhood obesity: changes and challenges

Reinehr, T. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.149 · Cited by 164 · see citing works

Safety of antiobesity drugs

Cheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 159 · see citing works

Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial

Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2003873 · Cited by 147 · see citing works

Comprehensive Review of Current and Upcoming Anti-Obesity Drugs

Son, J. W., & Kim, S. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0258 · Cited by 147 · see citing works

Adipose tissue: friend or foe?

Hassan, M. S., Latif, N., & Yacoub, M. H. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.148 · Cited by 142 · see citing works

Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management

Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136 · see citing works

Priming with Whole-Cell versus Acellular Pertussis Vaccine

Liko, J., Robison, S. G., & Cieslak, P. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1212006 · Cited by 128 · see citing works

The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

Fani, L., Bak, S., Delhanty, P., van Rossum, E. F. C., & van den Akker, E. L. T. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.80 · Cited by 121 · see citing works

Peripheral Serotonin: a New Player in Systemic Energy Homeostasis

Namkung, J., Kim, H., & Park, S. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0258 · Cited by 114 · see citing works

Medical treatment of obesity: The past, the present and the future

Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109 · see citing works

Use of prescription antiobesity drugs in the United States.

Hampp, C., Kang, E. M., & Borders‐Hemphill, V. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1342 · Cited by 103 · see citing works

From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists

Higgins, G. A., Sellers, E. M., & Fletcher, P. J. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.001 · Cited by 98 · see citing works

Weight management in obesity – past and present

Haslam, D. B. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12771 · Cited by 100 · see citing works

The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy

Fujioka, K., Plodkowski, R. A., O'Neil, P. M., Gilder, K. M., Walsh, B., & Greenway, F. L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.67 · Cited by 88 · see citing works

Nuciferine, an active ingredient derived from lotus leaf, lights up the way for the potential treatment of obesity and obesity-related diseases

Wan, Y., Xia, J., Xu, J., Chen, L., Yang, Y., Wu, J., Tang, F., Ao, H., & Peng, C. Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106002 · Cited by 86 · see citing works

The role of prolactin in andrology: what is new?

Rastrelli, G., Corona, G., & Maggi, M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9322-3 · Cited by 87 · see citing works

2014 EASO Position Statement on the Use of Anti-Obesity Drugs

Toplak, H., Woodward, E., Yumuk, V., Oppert, J., Halford, J. C. G., & Frühbeck, G. (2015) · Obesity Facts · doi:10.1159/000430801 · Cited by 83 · see citing works

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes

He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81 · see citing works

Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential

Higgins, G. A., Fletcher, P. J., & Shanahan, W. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107417 · Cited by 79 · see citing works

Epigenetic Regulation of Adipogenesis in Development of Metabolic Syndrome

Pant, R., Firmal, P., Shah, V. K., Alam, A., & Chattopadhyay, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.619888 · Cited by 78 · see citing works

Pharmacological strategies for targeting BAT thermogenesis

Whittle, A. J., Relat, J., & Vidal‐Puig, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.004 · Cited by 76 · see citing works

Tolerability and Safety of the New Anti-Obesity Medications

Hainer, V., & Aldhoon-Hainerová, I. (2014) · Drug Safety · doi:10.1007/s40264-014-0206-3 · Cited by 75 · see citing works

Molecular and Neural Functions of Rai1 , the Causal Gene for Smith-Magenis Syndrome

Huang, W., Guenthner, C. J., Xu, J., Nguyen, T., Schwarz, L. A., Wilkinson, A. W., Gozani, O., Chang, H. Y., Shamloo, M., & Luo, L. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.019 · Cited by 72 · see citing works

Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies

Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72 · see citing works

Update on obesity pharmacotherapy

Bray, G. A., & Ryan, D. H. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12328 · Cited by 88 · see citing works

Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity

Chung, H., Yu, J. G., Lee, I., Liu, M., Shen, Y., Sharma, S. P., Jamal, M. A. H. M., Yoo, J., Kim, H., & Hong, S. (2015) · FEBS Open Bio · doi:10.1002/2211-5463.12024 · Cited by 65 · see citing works

Obesity and Black Women: Special Considerations Related to Genesis and Therapeutic Approaches

Agyemang, P., & Powell‐Wiley, T. M. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0328-7 · Cited by 63 · see citing works

Dibenzazepine-Loaded Nanoparticles Induce Local Browning of White Adipose Tissue to Counteract Obesity

Jiang, C., Cano-Vega, M. A., Yue, F., Kuang, L., Narayanan, N., Uzunallı, G., Merkel, M. P., Kuang, S., & Deng, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.020 · Cited by 63 · see citing works

Pharmacotherapy for Patients with Obesity

Gadde, K. M., Apolzan, J. W., & Berthoud, H. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272815 · Cited by 55 · see citing works

Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration

Unett, D. J., Gatlin, J., Anthony, T. L., Buzard, D. J., Chang, S., Chen, C., Xiaohua, C., Dang, H. T., Frazer, J. M., Le, M. K., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.207670 · Cited by 55 · see citing works

Why are anti-obesity drugs stigmatized?

Halpern, B., & Halpern, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.995088 · Cited by 55 · see citing works

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg

Mancini, M. C., & de Melo, M. E. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0242-0 · Cited by 54 · see citing works

miR-21 mimic blocks obesity in mice: A novel therapeutic option

Lhamyani, S., Gentile, A., Giráldez‐Pérez, R. M., Feijoo‐Cuaresma, M., Romero‐Zerbo, S., Clemente‐Postigo, M., Zayed, H., Oliva‐Olivera, W., Bermúdez‐Silva, F. J., Salas, J., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.019 · Cited by 53 · see citing works

Prescriber's Guide

Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275 · Cited by 51 · see citing works

Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications

Halpern, B., & Halpern, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.994502 · Cited by 49 · see citing works

Luteolin reduces fat storage in Caenorhabditis elegans by promoting the central serotonin pathway

Yan, L., Yang, N., Bao, B., Wang, L., Chen, J., & Liu, J. (2019) · Food & Function · doi:10.1039/c9fo02095k · Cited by 49 · see citing works

Nanotechnology‐Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities

Tsou, Y., Wang, B., Ho, W., Hu, B., Tang, P. L., Sweet, S., Zhang, X., & Xu, X. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801184 · Cited by 48 · see citing works

The Regulatory Role of the Central and Peripheral Serotonin Network on Feeding Signals in Metabolic Diseases

Nonogaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031600 · Cited by 46 · see citing works

Heart Failure and Obesity: Translational Approaches and Therapeutic Perspectives. A Scientific Statement of the Heart Failure Association of the ESC

Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 50 · see citing works

Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice

Gadde, K. M., & Raj, Y. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0859-2 · Cited by 46 · see citing works

Precision Medicine in Weight Loss and Healthy Living

Severin, R. S., Sabbahi, A., Mahmoud, A. M., Arena, R. A., & Phillips, S. A. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.12.012 · Cited by 43 · see citing works

Pharmacologic Treatment Options for Obesity: What Is Old Is New Again

Ryan, D. H., & Bray, G. A. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0343-6 · Cited by 41 · see citing works

Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release

Halpern, B., & Mancini, M. C. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 42 · see citing works

Oolong tea polysaccharide and polyphenols prevent obesity development in Sprague–Dawley rats

Wu, T., Xu, J., Chen, Y., Liu, R., & Zhang, M. (2018) · Food & Nutrition Research · doi:10.29219/fnr.v62.1599 · Cited by 42 · see citing works

Combination phentermine and topiramate extended release in the management of obesity.

Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38 · see citing works

Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a Novel Peripherally Restricted Cannabinoid-1 Receptor Antagonist with Significant Weight-Loss Efficacy in Diet-Induced Obese Mice

Chang, C., Wu, C.-H., Song, J., Chou, M., Wong, Y., Lin, Y., Yeh, T., Sadani, A. A., Ou, M., Chen, K.-H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401158e · Cited by 37 · see citing works

Lifestyle Management for Enhancing Outcomes after Bariatric Surgery

Kalarchian, M., Turk, M., Elliott, J., & Gourash, W. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0540-y · Cited by 36 · see citing works

Vascular risk in obesity: Facts, misconceptions and the unknown

King, R., & Ajjan, R. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116675488 · Cited by 36 · see citing works

Fluoxetine for adults who are overweight or obese

Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011688.pub2 · Cited by 36 · see citing works

Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit

Cunningham, J. W., & Wiviott, S. D. (2014) · Clinical Cardiology · doi:10.1002/clc.22304 · Cited by 35 · see citing works

Lorcaserin for the treatment of obesity? A closer look at its side effects

DiNicolantonio, J. J., Chatterjee, S., O’Keefe, J. H., & Meier, P. (2014) · Open Heart · doi:10.1136/openhrt-2014-000173 · Cited by 35 · see citing works

Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy

Milano, W., Biasio, V. D., Munzio, W. D., Foggia, G., & Capasso, A. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200515112853 · Cited by 33 · see citing works

Drugs for Treating Obesity

Ryan, D. H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_560 · Cited by 35 · see citing works

New Pharmacological Treatments for the Management of Obesity

Hurt, R. T., Varayil, J. E., & Ebbert, J. O. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0394-0 · Cited by 32 · see citing works

Role of impulsivity and reward in the anti-obesity actions of 5-HT 2C receptor agonists

Higgins, G. A., Zeeb, F. D., & Fletcher, P. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117735797 · Cited by 33 · see citing works

Obesity an overview: Genetic conditions and recent developments in therapeutic interventions

Rao, V., Candasamy, M., & Bhattamisra, S. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.004 · Cited by 32 · see citing works

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice

PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 32 · see citing works

Serotonin Transporter Binding in the Diencephalon Is Reduced in Insulin-Resistant Obese Humans

Versteeg, R. I., Koopman, K. E., Booij, J., Ackermans, M. T., Unmehopa, U. A., Fliers, E., la Fleur, S. E., & Serlie, M. J. M. (2016) · Neuroendocrinology · doi:10.1159/000450549 · Cited by 32 · see citing works

Directly Observable Behavioral Effects of Lorcaserin in Rats

Serafine, K. M., Rice, K. C., & France, C. P. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228148 · Cited by 31 · see citing works

Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review

Conde, K., Fang, S., & Xu, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01091-7 · Cited by 32 · see citing works

Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2

Davidson, M. H., Tonstad, S., Oparil, S., Schwiers, M., Day, W. W., & Bowden, C. H. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.038 · Cited by 31 · see citing works

GUCY2C: at the intersection of obesity and cancer

Kim, G. W., Lin, J. E., & Waldman, S. A. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.001 · Cited by 31 · see citing works

Lorcaserin: A Review of its Use in Chronic Weight Management

Hoy, S. M. (2013) · Drugs · doi:10.1007/s40265-013-0035-1 · Cited by 29 · see citing works

Barriers and Solutions for Prescribing Obesity Pharmacotherapy

Fujioka, K., & Harris, S. R. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.007 · Cited by 28 · see citing works

Metabolic Benefits of MicroRNA-22 Inhibition

Thibonnier, M., & Esau, C. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0820 · Cited by 27 · see citing works

Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats

Gannon, B. M., Sulima, A., Rice, K. C., & Collins, G. T. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246082 · Cited by 26 · see citing works

Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease

Yang, Y., Huang, H., Xu, Z., & Duan, J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7680576 · Cited by 25 · see citing works

Patient Characteristics Associated with Receipt of Prescription Weight‐Management Medications Among Veterans Participating in MOVE!

Thomas, D. D., Waring, M. E., Ameli, O., Reisman, J. I., & Vimalananda, V. G. (2019) · Obesity · doi:10.1002/oby.22503 · Cited by 25 · see citing works

Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice

Gadde, K. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.890590 · Cited by 25 · see citing works

Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes

Ottney, A. R. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130081 · Cited by 25 · see citing works

Neuropeptide receptors as potential pharmacological targets for obesity

Meneguetti, B. T., Cardoso, M. H. E. S., Ribeiro, C. F. A., Felício, M. R., Pinto, I. B., Santos, N. C., Carvalho, C. M. E., & Franco, O. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.002 · Cited by 22 · see citing works

Phentermine

Lim, S., Rogers, L. K., Tessler, O., Mundinger, G. S., Rogers, C. L., & Lau, F. H. (2018) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000001478 · Cited by 20 · see citing works

Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review

Serralde-Zúñiga, A. E., Garay, A. G. G., Rodríguez‐Carmona, Y., & Meléndez, G. (2022) · Obesity Facts · doi:10.1159/000524995 · Cited by 20 · see citing works

The effect of antiobesity drugs on waist circumference: a mixed treatment comparison

Chilton, M., Dunkley, A. J., Carter, P., Davies, M. J., Khunti, K. K., & Gray, L. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12198 · Cited by 19 · see citing works

Lorcaserin for weight management

Taylor, J., Dietrich, E. A., & Powell, J. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s36276 · Cited by 19 · see citing works

Obesity and type 2 diabetes: can we find a compromised treatment solution?

Galstyan, G. R., Shestakova, E. A., & Sklyanik, I. A. (2017) · Diabetes Mellitus · doi:10.14341/dm8726 · Cited by 21 · see citing works

Antiobesity Pharmacotherapy for Patients with Type 2 Diabetes: Focus on Long-Term Management

Jeon, W. S., & Park, C.-Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.410 · Cited by 18 · see citing works

Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones

Behary, P., Cegla, J., Tan, T., & Bloom, S. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1048181 · Cited by 17 · see citing works

Obesity Management of Liver Transplant Waitlist Candidates and Recipients

Brandman, D. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.08.001 · Cited by 18 · see citing works

In vitro structure–activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety–depression model

Lewellyn, K., Białońska, D., Loria, M. J., White, S. W., Sufka, K. J., & Zjawiony, J. K. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.011 · Cited by 17 · see citing works

Effects of resistant dextrin for weight loss in overweight adults: a systematic review with a meta-analysis of randomized controlled trials

Mukai, J., Tsuge, Y., Yamada, M., Otori, K., & Atsuda, K. (2017) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-017-0084-9 · Cited by 17 · see citing works

Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures

Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16 · see citing works

The interaction between nutrition and the brain and its consequences for body weight gain and metabolism; studies in rodents and men

la Fleur, S. E., & Serlie, M. J. M. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.06.001 · Cited by 16 · see citing works

Gαi/o-coupled Htr2c in the paraventricular nucleus of the hypothalamus antagonizes the anorectic effect of serotonin agents

Yoo, E.-S., Li, L., Jia, L., Lord, C. C., Lee, C. E., Birnbaum, S. G., Vianna, C. R., Berglund, E. D., Cunningham, K. A., Xu, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109997 · Cited by 15 · see citing works

Treating the obese diabetic

Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 14 · see citing works

Unexpected Reaction Pathway for butyrylcholinesterase-catalyzed inactivation of “hunger hormone” ghrelin

Yao, J., Yuan, Y., Zheng, F., & Zhan, C. (2016) · Scientific Reports · doi:10.1038/srep22322 · Cited by 15 · see citing works

The FDA's Assessment of Two Drugs for Chronic Weight

Golden, J. K., Roberts, M. E., Egan, A., & Weaver, J. (2012)

Data on FDA-approved weight management medications dominate Obesity Week

Tanzi, M. G. (2015) · Pharmacy Today · doi:10.1016/s1042-0991(15)30333-9

Nuevas drogas en el tratamiento de la Obesidad y el Sobrepeso New drugs for the treatment of obesity and overweight

Politi, M. T., & Isolabella, D. (2013)

Weigh in on Weight loss Drugs

Moawad, F. J. (2015)

Comparison table: Some FDA-approved drugs for weight management.

(2022) · PubMed · Cited by 1 · see citing works